⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317139 | 0.77 | — | — | |
| SCHEMBL8319545 | 0.71 | — | — | |
| SCHEMBL128750 | 0.71 | — | — | |
| SCHEMBL3904380 | 0.71 | — | — | |
| SCHEMBL4348861 | 0.67 | LMNA (0.32) | — | |
| SCHEMBL10892585 | 0.67 | — | — | |
| SCHEMBL7441681 | 0.67 | — | — | |
| SCHEMBL8634521 | 0.64 | — | — | |
| SCHEMBL10457316 | 0.64 | — | — | |
| SCHEMBL2219660 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022238500-A1 | RADIOSYNTHESIS OF [18F] TALAZOPARIB | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4088745-A1 | COMPOUND FOR THE DIAGNOSIS OF CANCER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2022-11-16 | — | — | EP | disclosed |
| EP-4089093-A1 | RADIOSYNTHESIS OF [18F] TALAZOPARIB | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2022-11-16 | — | — | EP | disclosed |
| WO-2018009856-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE AND OTHER OPIATES | CODY LABORATORIES, INC. (US) | 2018-01-11 | — | — | WO | disclosed |
| US-9783535-B2 | Substituted noribogaine | DEMERX, INC. | 2017-10-10 | — | — | US | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| CN-105683182-A | Biaryl acetamide compounds and methods of use thereof | 埃姆比特生物科学公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20150361080-A1 | SUBSTITUTED NORIBOGAINE | DEMERX, INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150329536-A1 | SUBSTITUTED NORIBOGAINE | DEMERX, INC. | 2015-11-19 | — | — | US | disclosed |
| EP-0873311-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-10-28 | — | — | EP | disclosed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0858999-A1 | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5710170-A | Tri-aryl ethane derivatives as PDE IV inhibitors | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| WO-1997022586-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-06-26 | — | — | WO | disclosed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0746614-A1 | METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995023225-A2 | METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |